Glucagon-Like Peptide-1 Receptor Agonists and Risk of Macular Degeneration
1–10 of 12 posts
Re: Glucagon-Like Peptide-1 Receptor Agonists and Risk of Macular Degeneration
#2Re: Glucagon-Like Peptide-1 Receptor Agonists and Risk of Macular Degeneration
#3Emphasis mine, but it's important context that probably wouldn't fit in the title.
Re: Glucagon-Like Peptide-1 Receptor Agonists and Risk of Macular Degeneration
#4Re: Glucagon-Like Peptide-1 Receptor Agonists and Risk of Macular Degeneration
#5139,000 patients, hazard went from 0.1 to 0.2%. It means that 139 new patients developed Macular Degeneration during 3 years. I would really consider the benefits of GLP-1 versus health gains to diabetic patients (specially regarding quality of life with macular degeneration)
Re: Glucagon-Like Peptide-1 Receptor Agonists and Risk of Macular Degeneration
#6Re: Glucagon-Like Peptide-1 Receptor Agonists and Risk of Macular Degeneration
#7Re: Glucagon-Like Peptide-1 Receptor Agonists and Risk of Macular Degeneration
#8139,000 patients, hazard went from 0.1 to 0.2%. It means that 139 new patients developed Macular Degeneration during 3 years. I would really consider the benefits of GLP-1 versus health gains to diabetic patients (specially regarding quality of life with macular degeneration)
Of course hard to extrapolate to the general case from this study, as it only included patients over 66 with a diagnosis of diabetes.
Re: Glucagon-Like Peptide-1 Receptor Agonists and Risk of Macular Degeneration
#9Re: Glucagon-Like Peptide-1 Receptor Agonists and Risk of Macular Degeneration
#10It's important to note that macular degeneration is caused by diabetes. So what would the rate of degeneration be without GLP-1s helping control blood sugar? My guess is much, much higher.